Clinical trials: Non Small Cell Lung Cancer Stage IIIB
Lung Cancer
Mistletoe in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Are Receiving Palliative Chemotherapy
RATIONALE: Mistletoe may help the body build an immune response and may improve quality of life to help patients live more comfortably.
- Trial name
- NCT00052325
- Testing
- mistletoe extract
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lung Cancer
Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00526890
- Testing
- selenomethionine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
This phase I trial studies the best dose of radiation therapy in treating patients with locally advanced non-small cell lung cancer that cannot be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells.
- Conditions
- Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT01711697
- Testing
- stereotactic body radiation therapy, carboplatin, paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Emory University
Non-Small Cell Lung Cancer
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This open-label, multi-center study will evaluate the progression-free survival and safety of erlotinib in participants with locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine…
- Trial name
- ESSENCE (NCT01667562)
- Testing
- Erlotinib
- Where
- 4 sites in Serbia
- Volunteers
- 375 people
- Sponsor
- Hoffmann-La Roche
Non-small-cell Lung Cancer
Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)
Present study is to investigate efficacy and toxicity profiles of induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
- Trial name
- NCT00686322
- Testing
- Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer
This phase II trial studies how well pembrolizumab works in treating patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer that have not received prior tyrosine kinase inhibitor therapy and has…
- Conditions
- Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02879994
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab.
- Trial name
- NCT06623422
- Testing
- Pembrolizumab, Cisplatin, Carboplatin
- Where
- 245 sites in United States, Argentina and 29 more
- Volunteers
- 680 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00118131
- Testing
- cisplatin, docetaxel
- Where
- 13 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Metastatic Malignant Neoplasm in the Lung, Stage IIIB Non-Small Cell Lung Cancer
Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis
This phase I trial studies the side effects and best dose of cisplatin in treating patients with stage IIIB-IV non-small cell lung cancer or tumors that have spread from where they started to the lung (metastasis).
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT01014598
- Testing
- Cisplatin, Pharmacological Study
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Roswell Park Cancer Institute
NSCLC Stage IV, NSCLC Stage IIIB
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
For metastatic/advanced NSCLC patients who do not have targetable mutations, either immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in combination with platinum doublet chemotherapy is now…
- Trial name
- Ipat-Lung (NCT04467801)
- Testing
- Ipatasertib
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Jun Zhang, MD, PhD
Lung Cancer
Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00081302
- Testing
- cetuximab, carboplatin, paclitaxel
- Where
- United States
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer, Metastatic Cancer
Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
RATIONALE: Cryotherapy kills tumor cells by freezing them. This may be an effective treatment for primary lung cancer or lung metastases that cannot be removed by surgery.
- Trial name
- NCT00303901
- Testing
- cryosurgery, positron emission tomography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lung Cancer
Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying vaccine therapy given after standard therapy to see how well it works in treating patients with stage…
- Trial name
- NCT00019929
- Testing
- mutant p53 peptide pulsed dendritic cell vaccine, adjuvant therapy
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck
This phase I/II trial is studying the side effects of erlotinib and to see how well it works in treating patients with metastatic or unresectable non-small cell lung cancer, ovarian cancer, or squamous cell carcinoma (cancer) of…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00063895
- Testing
- erlotinib hydrochloride, pharmacological study, pharmacogenomic studies
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy of gemcitabine/cisplatin versus gemcitabine/epirubicin in Stage IIIB/IV NSCLC in terms of response rate and overall survival.
- Trial name
- NCT00154739
- Testing
- Gemcitabine, Cisplatin, Epirubicin
- Where
- Taiwan
- Volunteers
- 86 people
- Sponsor
- National Taiwan University Hospital
Lung Cancer
Gemcitabine Plus Carboplatin or Cisplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004201
- Testing
- carboplatin, cisplatin, gemcitabine hydrochloride
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Lung Cancer
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00310154
- Testing
- docetaxel, gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Wake Forest University Health Sciences
Lung Cancer
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00023673
- Testing
- carboplatin, paclitaxel, three-dimensional conformal radiation therapy
- Where
- 41 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with advanced lung cancer that…
- Trial name
- NCT00570401
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
The main purpose of this first study combining an investigational dual mTOR inhibitor, CC-223, with other agents (erlotinib or the investigational agent, oral azacitidine) is to establish a maximum tolerated dose level for each…
- Trial name
- NCT01545947
- Testing
- CC-223, erlotinib, CC-223, oral azacitidine
- Where
- 9 sites in United States, Spain
- Volunteers
- 76 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.